Protocol Ledger

NCT07419334 · Phase III · RECRUITING

Study of ALK-001 on the Progression of Stargardt Disease

Interventional Phase III clinical trial protocol NCT07419334 sponsored by Alkeus Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-03 Enrollment: 230 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07419334
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)230 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07419334
Protocol FieldVerified Registry Value
NCT IdentifierNCT07419334
Consolidated Lead SponsorAlkeus Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment230 participants (ESTIMATED)
Registered Start Date2026-06-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07419334
Hospital Research SiteLocationSite Profile
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI